Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Europe and Israel or involving organisations from these countries.

Total search results: 9650 | Ordered by Date (ascending)
next pagenext page 1 2 3 ... 95 96 97  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Sirion Biotech–Cevec: cell lines, 201312– license €na to CAP cell lines for expression of AAV vectors 2013-12-19
ATMI–Pall Corp: investment, 201312–201402 acquisition $185m net $165m of ATMI Life Sciences by Pall 2013-12-23
AAIPharma Services–Cambridge Major Laboratories: investment, 201312 merger in late 2013 2013-12-31
Alma Bio Therapeutics–Delphi Genetics: plasmid DNA drugs, 2014– collab strategic alliance w Delphi producing plasmid DNA drugs using Staby technology 2014-01-01
ArchiMed–SEVERAL: investment, 2014 closing of MED I Fund at €150m 2014-01-01
Electrochaea–SEVERAL: investment, 2014 financing round Series A 2014-01-01
genOway–Institut Pasteur: transgenic anmials, 2014– license excl to patent portfolio for technology for transgenic rodent research models 2014-01-01
Horizon Discovery–ERS Genomics: CRISPR technology, 2014– license ww non-excl to Horizon 2014-01-01
Mestex–SEVERAL: investment, 2014 1st financing round 2014-01-01
Optos–Nikon: investment, 2014 acquisition $400m of Optops plc by Nikon 2014-01-01
OxSyBio–SEVERAL: investment, 2014c seed financing round £1m 2014-01-01
Provecs–Cevec: rec protein production technology, 2014– license to CAP GT technology for cancer immunotherapy 2014-01-01
Rebiotix–SEVERAL: investment, 2014 financing round Series B $25m 2014-01-01
Sanofi–MyoKardia: cardiovascular drugs, 2014–201903 collab RnD NOT PROLONGED all rights returned to MyoKardia 201904 2014-01-01
Sirion Biotech–LaVoieHealthScience: public relations, 2014– supply service US PR/IR 2014-01-01
Tusk Therapeutics–Droia Ventures: investment, 201809 existent majority shareholder + founding investor Droia Oncology Ventures 2014-01-01
Cadence Pharmaceuticals–Mallinckrodt: investment, 201402 acquisition $1.3b cash tender offer by Mallinkcrodt plc 2014-02-11
Synaffix–Aravis: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital 2014-02-18
Synaffix–BioGeneration Ventures: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital 2014-02-18
Synaffix–BOM Capital: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital 2014-02-18
Synaffix–Merck (DE): investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital 2014-02-18
Axonics–LCF Rothschild: investment, 201403 investment by EdRIP 2014-03-01
Ono Pharmaceutical–Merus: bispecific antibodies, 201404– collab research + license agreem to develop bispecific ABs for autoimmune diseases 2014-04-01
Essen BioScience–SFW Capital Partners: investment, 201405 strategic investment in Essen BioScience by SFW 2014-04-15
Principia Biopharma–SEVERAL: investment, 201404 financing round Series B $50m led by Sofinnova Ventures 2014-04-22
Principia Biopharma–SEVERAL: investment, earlier than 201404 financing round Series A $40m 2014-04-22
B Braun–CeGaT: personalised medicine, 201406 collab establishment of B Braun CeGaT LLC in Pennsylvania 2014-06-01
Step Pharma–Eurazeo: investment, 201406 founding investor Kurma Biofund II 2014-06-01
Allogene Therapeutics–Pfizer: T-cell immunotherapy, 201804 asset contribution agreem for Pfizer’s allogeneic CAR T immuno-oncology pipeline 2014-06-18
AbbVie–Apogenix: TRAIL receptor agonists, 201407 aquisition of ww rights to all TRAIL receptor agonists of Apogenix by AbbVie 2014-07-01
Geisinger–Indivumed: tissue bank, 201407– collab to create cancer research biobanks at Geisinger + Indivumed 2014-07-15
i3 Membrane–SEVERAL: investment, 201408 investment by HTGF + Innovationsstarter Fonds Hamburg 2014-08-01
Paragon Bioservices–Camden Partners: investment, 201410 financing round Series A Preferred Stock led by NewSpring Capital + Camden Partners 2014-10-01
Paragon Bioservices–NewSpring Capital: investment, 201410 financing round Series A Preferred Stock led by NewSpring Capital + Camden Partners 2014-10-01
Paragon Bioservices–SEVERAL: investment, 201410 financing round Series A Preferred Stock led by NewSpring Capital + Camden Partners 2014-10-01
Roche–NewLink Genetics: cancer drugs, 201410– collab drug discovery IDO/TDO inhibitors with Genentech 2014-10-16
Pepperprint–Sciomics: microarray technology, 201411– collab distribution + marketing for antibody characterisation + biomarker discovery 2014-11-18
Tiziana–Novimmune: therapeutic antibody, 201412– license to foralumab (NI-0401) to Tiziana 2014-12-01
iTeos Therapeutics–Pfizer: investment, 201412 equitiy investment by Pfizer as part of cancer immunotherapy license + collab agreem 2014-12-08
Pfizer–iTeos Therapeutics: cancer immunotherapy, 201412– license for 2 compounds + collab target discovery €24m upfront + investm + milestones et al 2014-12-08
Annexon–Clarus Ventures: investment, 201412 financing round Series A-1 totaliing $34m incl co-investor Clarus Ventures 2014-12-15
Annexon–Novartis: investment, 201412 financing round Series A-1 totaliing $34m incl lead investor NVF 2014-12-15
Annexon–Satter Investment Management: investment, 201412 financing round Series A-1 totaliing $34m incl co-investor Satter 2014-12-15
Annexon–SEVERAL: investment, 201412 financing round Series A-1 $34m led by NVF + incl Satter Investment + Clarus Ventures 2014-12-15
Cristal Therapeutics–BioGeneration Ventures: investment, 201412 financing round totalling €6m incl existing investor BGV 2014-12-15
Cristal Therapeutics–Chemelot Ventures: investment, 201412 financing round totalling €6m incl new investor Chemelot Ventures 2014-12-15
Cristal Therapeutics–Limburg (NL) (govt): investment, 201412 financing round totalling €6m incl existing investors Nedermaas + Innovatiefonds Limburg 2014-12-15
Cristal Therapeutics–Thuja Capital: investment, 201412 financing round totalling €6m incl existing investor Thuja Capital 2014-12-15
Cristal Therapeutics–Univ Utrecht: investment, 201412 financing round totalling €6m incl existing investor Utrecht University Holdings 2014-12-15
Pieris–Ally Bridge Group: investment, 201412 private placement totalling $13.56m incl investor ABG 2014-12-18
Aquila Biolabs–SEVERAL: investment, 2015 seed financing round 7-digit € 2015-01-01
Atomwise–SEVERAL: investment, 2015 seed financing round incl Y Combinator + Khosla Ventures + DJF 2015-01-01
B Medical Systems–Navis Capital: investment, 2015 acquisition of Medical Dvision of Dometic by Navis Capital creating B Medical Systems 2015-01-01
BIO (US)–Inova Software: business partnering software, 2015– collab using One-on-One for BIO Annual Convention 2015-01-01
Biocentric–Hain Lifescience: investment, 2015 acquisition of Biocentric by Hain 2015-01-01
Boston Biotech Conference–Informa: investment, 2015 acquisition 100% £12.7m in cash net of cash acquired 2015-01-01
ClinicPoint–SEVERAL: investment, 2015 funding €1m total private investment attracted over the year 2015 2015-01-01
Corvidia Therapeutics–Sofinnova: investment, 2015 seed financing from Sofinnova Partners 2015-01-01
Enyo Pharma–SEVERAL: investment, 2015 seed financing round €2.2m 2015-01-01
Galgo Medical–SEVERAL: investment, 2015 funding €1m total private investment attracted over the year 2015 2015-01-01
Gemedica Therapeutics–SEVERAL: investment, 2015 funding €2.5m total private investment attracted over the year 2015 2015-01-01
Greenaltech–SEVERAL: investment, 2015 funding €2m total private investment attracted over the year 2015 2015-01-01
GreenBone–SEVERAL: investment, 2015 seed financing round €3m from ZernikeMeta Ventures + Italian Angels for Growth + private investors 2015-01-01
iSalud–SEVERAL: investment, 2015 funding €1m total private investment attracted over the year 2015 2015-01-01
Jecure Therapeutics–Versant Ventures: investment, 2015 seed financing from founding investor Versant Ventures 2015-01-01
KBI BioPharma–JSR Corp: investment, 2015 acquisition of KBI BioPharma Inc by JSR Corp 2015-01-01
KSQ Therapeutics–Alexandria Real Estate: investment, 2015–201710 financing totalling $76m incl co-investor Alexandria Equities 2015-01-01
KSQ Therapeutics–ARCH Venture: investment, 2015–201710 financing totalling $76m incl co-investor ARCH Venture Partners 2015-01-01
KSQ Therapeutics–Flagship Pioneering: investment, 2015–201710 financing totalling $76m incl lead + founding investor Flagship Pioneering 2015-01-01
KSQ Therapeutics–Polaris Partners: investment, 2015–201710 financing totalling $76m incl co- + founding investor Polaris Partners 2015-01-01
KSQ Therapeutics–SEVERAL: investment, 2015–201710 financing $76m from Flagship + Polaris + ARCH + Alexandria as KSQ emerges from stealth 2015-01-01
Kurma–SEVERAL: investment, 2015 final closing €35m of Kurma Diagnostics Fund (KDx) 2015-01-01
Medtep–SEVERAL: investment, 2015 funding €1.8m total private investment attracted over the year 2015 2015-01-01
Morphogen-IX–Cambridge Innovation Capital: investment, 2015 seed financing round from Medicxi + Cambridge Innovation Capital + Cambridge Enterprise 2015-01-01
Morphogen-IX–Medicxi Ventures: investment, 2015 seed financing round from Medicxi + Cambridge Innovation Capital + Cambridge Enterprise 2015-01-01
Morphogen-IX–SEVERAL: investment, 2015 seed financing round from Medicxi + Cambridge Innovation Capital + Cambridge Enterprise 2015-01-01
Morphogen-IX–Univ Cambridge: investment, 2015 seed financing round from Medicxi + Cambridge Innovation Capital + Cambridge Enterprise 2015-01-01
Novartis–Fraunhofer: cell therapy production, 201501– collab developm of production capacity for Kymriah in Europe at Fraunhofer IZI 2015-01-01
Novartis–Fraunhofer: cell therapy production, 201808– service supply production of Kymriah in Europe by Fraunhofer IZI 2015-01-01
Primm Pharma–Xbrane: investment, 2015 acquisition of Primm Pharma srl by Xbrane BioScience AB 2015-01-01
Psious–SEVERAL: investment, 2015 funding €1m total private investment attracted over the year 2015 2015-01-01
Roche–4D Molecular Therapeutics: gene delivery technology, 2015– collab research 2015-01-01
Top Doctors–SEVERAL: investment, 2015 funding €1.1m total private investment attracted over the year 2015 2015-01-01
Transplant Biomedicals–SEVERAL: investment, 2015 funding €1.5m total private investment attracted over the year 2015 2015-01-01
VIB–Lipotype: mass spectrometry services, 2015– collab supply of shotgun lipidomics services by Lipotype to researchers at VIB 2015-01-01
ViraTherapeutics–Austria (govt): investment, 2015c financing €1.6m from FFG + aws seed financing programme 2015-01-01
Baxalta–Symphogen: cancer immunotherapy, 201601– collab strategic ww €160m upfront + €1.4b milestones + roaylties in immuno-oncology 2015-01-04
Alcobra–LifeSci: public relations, 201501 service existent US investor relations by LifeSci Advisors 2015-01-09
Alcobra–Sam Brown: public relations, 201501 service existent by Sam Brown Inc 2015-01-09
Fluidic Analytics–SEVERAL: investment, 201501 financing round Series A £1.56m ($2.4m) led by Cambridge Enterprise 2015-01-12
Boehringer–Vanderbilt Univ: Ras inhibitors, 201703– collab expansion RnD small-molecule KRAS inhibitors for cancer 2015-01-13
HiberGene–SEVERAL: investment, 201502 financing round Series A €2m 2015-02-01
R2R Biofluidics project–EU (govt): grant, 201502–201901 H2020 grant €6.4m out of total budget of €7.9m 2015-02-01
G1 Therapeutics–SEVERAL: investment, 201502 financing round Series B $33m co-led by Eshelman Ventures + RA Capital Management 2015-02-05
Synthace–SEVERAL: investment, 201502 financing round £2.2m incl SOSventures + Bioeconomy Capital et al 2015-02-11
Genenta Science–SEVERAL: investment, 201503 financing round Series A €10m 2015-03-01
OpGen–SEVERAL: investment, 201503–201505 IPO $17.1m+$2.565m with 2.85m+427.5k units consisting of 1 share + 1 warrant at $6/unit 2015-03-03
Macrolide–Bertarelli Group: investment, 201503 financing round Series A totalling $22m inc co-lead investor Gurnet Point Capital 2015-03-04
Macrolide–GSK: investment, 201503 financing round Series A totalling $22m inc co-lead investor SROne 2015-03-04
Macrolide–Novartis: investment, 201503 financing round Series A totalling $22m inc co-lead investor Novartis Venture Fund 2015-03-04
next pagenext page 1 2 3 ... 95 96 97  next pagenext page



Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Advertisement

Picture Berlin Partner Cardiovascular Health in Berlin-Brandenburg 650x300px

» top